India Cuts Off U.S. from Nearly Half of Its Hydroxychloroquine Supply
India, which sources nearly half of the U.S. supply of hydroxychloroquine, has banned the drug’s export “without any exceptions” effective immediately, India’s Directorate General of Foreign Trade said in an April 4 order on its website.
As of Monday, India has recorded 3,374 positive cases and has lost 77 lives, according to its federal health ministry. Trump said on Saturday that he had spoken to Indian Prime Minister Narendra Modi and revealed that India is giving “serious consideration” to the release of shipments U.S. has already ordered.
A Bloomberg News analysis found that 47 percent of the U.S. supply of hydroxychloroquine last year came from Indian manufacturers, including the top U.S. supplier, Zydus Pharmaceuticals Inc., which is a subsidiary of Ahmedabad, India-based Cadila Healthcare Ltd. It sold over 167 million units of the anti-malarial in 2019, and has supplied 28 million to the U.S. market so far this year.
India, which sources nearly half of the U.S. supply of hydroxychloroquine, has banned the drug’s export “without any exceptions” effective immediately, India’s Directorate General of Foreign Trade said in an April 4 order on its website.
As of Monday, India has recorded 3,374 positive cases and has lost 77 lives, according to its federal health ministry. Trump said on Saturday that he had spoken to Indian Prime Minister Narendra Modi and revealed that India is giving “serious consideration” to the release of shipments U.S. has already ordered.
A Bloomberg News analysis found that 47 percent of the U.S. supply of hydroxychloroquine last year came from Indian manufacturers, including the top U.S. supplier, Zydus Pharmaceuticals Inc., which is a subsidiary of Ahmedabad, India-based Cadila Healthcare Ltd. It sold over 167 million units of the anti-malarial in 2019, and has supplied 28 million to the U.S. market so far this year.
